An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults.
There is no parenteral formulation of the neuraminidase inhibitor oseltamivir, the most widely used anti-influenza virus drug. Oseltamivir resistance is an increasing problem. Zanamivir is effective against the most prevalent oseltamivir-resistant influenza viruses. A parenteral formulation of zanam...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2011
|
| _version_ | 1797068964311859200 |
|---|---|
| author | Pukrittayakamee, S Jittamala, P Stepniewska, K Lindegardh, N Chueasuwanchai, S Leowattana, W Phakdeeraj, A Permpunpanich, S Hanpithakpong, W Pan-Ngum, W Fukuda, C Panapipat, S Singhasivanon, P White, N Day, N |
| author_facet | Pukrittayakamee, S Jittamala, P Stepniewska, K Lindegardh, N Chueasuwanchai, S Leowattana, W Phakdeeraj, A Permpunpanich, S Hanpithakpong, W Pan-Ngum, W Fukuda, C Panapipat, S Singhasivanon, P White, N Day, N |
| author_sort | Pukrittayakamee, S |
| collection | OXFORD |
| description | There is no parenteral formulation of the neuraminidase inhibitor oseltamivir, the most widely used anti-influenza virus drug. Oseltamivir resistance is an increasing problem. Zanamivir is effective against the most prevalent oseltamivir-resistant influenza viruses. A parenteral formulation of zanamivir is in development for the treatment of severe influenza. It is not known if there is any pharmacokinetic interaction between the two drugs. Sixteen healthy Thai adult volunteers were studied in an open-label, four-period, randomized two-sequence crossover pharmacokinetic study in which zanamivir was given by constant-rate infusion or slow intravenous injection either alone or together with oral oseltamivir. Plasma concentration profiles of oseltamivir, the active metabolite oseltamivir carboxylate, and zanamivir were measured by liquid chromatography-mass spectrometry-mass spectrometry. Both drugs were well tolerated alone and in combination. The maximum plasma concentrations and the areas under the plasma concentration-time curves (AUC) of oseltamivir and oseltamivir carboxylate were not significantly different when oseltamivir was given separately or together with zanamivir. Maximum plasma concentrations of zanamivir were 10% (95% confidence interval, 7 to 12%) higher when zanamivir was infused concurrently with oral oseltamivir than with infusions before or after oral oseltamivir. The plasma zanamivir total AUC was positively correlated with the total oseltamivir carboxylate AUC (Pearson's correlation coefficient [r(P)] = 0.720, P = 0.002, n = 16) but not with the oseltamivir AUC (r(p) = 0.121, n = 16). There is no clinically significant pharmacokinetic interaction between oseltamivir and zanamivir. |
| first_indexed | 2024-03-06T22:17:36Z |
| format | Journal article |
| id | oxford-uuid:53ee7554-ce1b-45da-af7a-ef37bb5231cb |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:17:36Z |
| publishDate | 2011 |
| record_format | dspace |
| spelling | oxford-uuid:53ee7554-ce1b-45da-af7a-ef37bb5231cb2022-03-26T16:34:40ZAn open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:53ee7554-ce1b-45da-af7a-ef37bb5231cbEnglishSymplectic Elements at Oxford2011Pukrittayakamee, SJittamala, PStepniewska, KLindegardh, NChueasuwanchai, SLeowattana, WPhakdeeraj, APermpunpanich, SHanpithakpong, WPan-Ngum, WFukuda, CPanapipat, SSinghasivanon, PWhite, NDay, NThere is no parenteral formulation of the neuraminidase inhibitor oseltamivir, the most widely used anti-influenza virus drug. Oseltamivir resistance is an increasing problem. Zanamivir is effective against the most prevalent oseltamivir-resistant influenza viruses. A parenteral formulation of zanamivir is in development for the treatment of severe influenza. It is not known if there is any pharmacokinetic interaction between the two drugs. Sixteen healthy Thai adult volunteers were studied in an open-label, four-period, randomized two-sequence crossover pharmacokinetic study in which zanamivir was given by constant-rate infusion or slow intravenous injection either alone or together with oral oseltamivir. Plasma concentration profiles of oseltamivir, the active metabolite oseltamivir carboxylate, and zanamivir were measured by liquid chromatography-mass spectrometry-mass spectrometry. Both drugs were well tolerated alone and in combination. The maximum plasma concentrations and the areas under the plasma concentration-time curves (AUC) of oseltamivir and oseltamivir carboxylate were not significantly different when oseltamivir was given separately or together with zanamivir. Maximum plasma concentrations of zanamivir were 10% (95% confidence interval, 7 to 12%) higher when zanamivir was infused concurrently with oral oseltamivir than with infusions before or after oral oseltamivir. The plasma zanamivir total AUC was positively correlated with the total oseltamivir carboxylate AUC (Pearson's correlation coefficient [r(P)] = 0.720, P = 0.002, n = 16) but not with the oseltamivir AUC (r(p) = 0.121, n = 16). There is no clinically significant pharmacokinetic interaction between oseltamivir and zanamivir. |
| spellingShingle | Pukrittayakamee, S Jittamala, P Stepniewska, K Lindegardh, N Chueasuwanchai, S Leowattana, W Phakdeeraj, A Permpunpanich, S Hanpithakpong, W Pan-Ngum, W Fukuda, C Panapipat, S Singhasivanon, P White, N Day, N An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults. |
| title | An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults. |
| title_full | An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults. |
| title_fullStr | An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults. |
| title_full_unstemmed | An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults. |
| title_short | An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults. |
| title_sort | open label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy thai adults |
| work_keys_str_mv | AT pukrittayakamees anopenlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT jittamalap anopenlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT stepniewskak anopenlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT lindegardhn anopenlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT chueasuwanchais anopenlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT leowattanaw anopenlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT phakdeeraja anopenlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT permpunpanichs anopenlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT hanpithakpongw anopenlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT panngumw anopenlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT fukudac anopenlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT panapipats anopenlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT singhasivanonp anopenlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT whiten anopenlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT dayn anopenlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT pukrittayakamees openlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT jittamalap openlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT stepniewskak openlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT lindegardhn openlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT chueasuwanchais openlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT leowattanaw openlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT phakdeeraja openlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT permpunpanichs openlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT hanpithakpongw openlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT panngumw openlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT fukudac openlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT panapipats openlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT singhasivanonp openlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT whiten openlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults AT dayn openlabelcrossoverstudytoevaluatepotentialpharmacokineticinteractionsbetweenoraloseltamivirandintravenouszanamivirinhealthythaiadults |